96. Crohn disease Clinical trials / Disease details

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

9 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00801125 (ClinicalTrials.gov)	December 2008	1/12/2008	Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-a Therapy	A Phase IV, Open-Label Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-a Therapy	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Withdrawn	18 Years	N/A	Both	0	Phase 4	NULL
2	NCT00707512 (ClinicalTrials.gov)	June 2008	27/6/2008	CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring	INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring	Crohn's Disease	Drug: natalizumab	Biogen	NULL	Terminated	18 Years	N/A	Both	87	N/A	United States;Puerto Rico
3	EUCTR2004-003839-31-DK (EUCTR)	05/02/2005	17/05/2005	A Phase III, Multicenter, Open-Label, Long-Term Study of the Tolerability of Intravenous Natalizumab in Crohn's Disease Subjects Who Have Previously Participated in Natalizumab Crohn's Disease Study CD351 - CD354	A Phase III, Multicenter, Open-Label, Long-Term Study of the Tolerability of Intravenous Natalizumab in Crohn's Disease Subjects Who Have Previously Participated in Natalizumab Crohn's Disease Study CD351 - CD354	Crohn's Disease (CD)	Product Name: natalizumab Product Code: AN100226 INN or Proposed INN: natalizumab	Elan Pharma Ltd.	NULL	Not Recruiting			Female: yes Male: yes	1000	Phase 3	Denmark
4	NCT00078611 (ClinicalTrials.gov)	March 2004	1/3/2004	A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease	A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous Antegren(TM) (Natalizumab) in Subjects With Moderately to Severely Active Crohn's Disease With Elevated C-Reactive Protein	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Completed	18 Years	N/A	Both	462	Phase 3	United States;Canada
5	NCT00280956 (ClinicalTrials.gov)	July 2002	21/1/2006	Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease	A Phase III, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren™ (Natalizumab) in Crohn's Disease Subjects Who Have Previously Participated in Antegren Crohn's Disease Studies	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Completed	18 Years	N/A	Both	2000	Phase 4	United States
6	NCT00055367 (ClinicalTrials.gov)	April 2002	26/2/2003	Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease	A Phase II, International, Multicenter, Open Label Study of the Safety, Tolerability and Effectiveness of Three Intravenous Infusions of Antegren (Natalizumab) in Adolescents With Moderately to Severely Active Crohn's Disease	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Completed	12 Years	17 Years	Both	30	Phase 2	United States;United Kingdom
7	NCT00055536 (ClinicalTrials.gov)	April 2002	4/3/2003	Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease	A Phase II, Multi-Center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren (Natalizumab) in Crohn's Disease Subjects Concurrently Receiving Remicade (Infliximab) and Not in Remission	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Completed	18 Years	N/A	Both	60	Phase 2	United States
8	NCT00032786 (ClinicalTrials.gov)	March 2002	3/4/2002	Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease	A Phase 3, International, Multicenter, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Antegren (Natalizumab) in Maintaining Clinical Response and Remission in Subjects With Crohn's Disease	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Completed	18 Years	N/A	Both		Phase 3	NULL
9	NCT00032799 (ClinicalTrials.gov)	December 2001	3/4/2002	Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease	A Phase 3 International, Multicenter, Double-blind, Placebo-controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren (Natalizumab) in Subjects With Moderate to Severely Active Crohn's Disease	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Completed	18 Years	N/A	Both	905	Phase 3	United States